Citi maintains ‘Sell' call on Dr. Reddy's stock after its Q4 FY25 results
Citi has maintained its 'Sell' rating on Dr. Reddy's Laboratories, with a target price of ₹1,110, even after the company posted a strong Q4 beat on net profit and revenue. The brokerage remains focused on underlying margin pressure and operational concerns.
Despite revenue climbing 20.1% YoY and profit jumping to ₹1,587 crore, Citi flagged that gross margins continued to decline, and noted that FY26 guidance appears ambitious given ongoing pricing pressures and slow India growth.
Citi expects the next quarter to benefit from peak generic Revlimid (gRevlimid) volumes, but said this will not be sustainable in the long term. While long-term opportunities in GLP-1 drugs and biosimilars remain attractive, Citi believes the near-term setup is less favourable and warrants caution.
Markets Desk at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Tesla Sales Fall 13%
Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after the closing bell on Wall Street. Today's guests are Zachary Griffiths, CreditSights Anthony Pompliano CEO of Professional Capital Management, Dan Levy Barclays, Ralf Reichert Esports World Cup Foundation, Sandy Pomeroy Neuberger Berman Group LLC, Kevin Brady Akin, Stephanie Kelton Stony Brook University, Nathan Sheets Citi, Jacqui Canney Servicenow, and Deon Nicholas Forethought. (Source: Bloomberg)
Business Journals
7 hours ago
- Business Journals
Beyond the headlines: How the Big Beautiful Bill threatens Sacramento's workforce and economy
In every corner of Sacramento, from bustling downtown offices to family-run shops in Oak Park, the heartbeat of our economy is the same: working people striving to build a better life. They are parents juggling jobs and childcare, students working their way through school and caregivers holding families together. They are the backbone of our businesses—and when they thrive, we all do. That's why we must speak plainly and urgently about H.R.-1, known in Congress as the 'Big Beautiful Bill.' Behind its polished name lies a set of policies that would do real harm to the people who make Sacramento work. This bill doesn't just threaten social programs—it threatens the very foundation of our local economy. Let's be clear. This isn't about partisanship. It's about people. It's about practical economics. And it's about the kind of leadership our business community is called to show in moments like this. H.R.-1 proposes deep cuts to Medicaid (Medi-Cal in California) and SNAP (CalFresh). It will sharply limit access to the Earned Income Tax Credit, the Child Tax Credit and student loan forgiveness. These aren't handouts. They are investments—investments in health, in education and in stability. They are the scaffolding that allows working families to show up, stay healthy and contribute fully to our economy. In the districts of Congresswoman Doris Matsui and Congressman Ami Bera—covering Sacramento County and part of Yolo County—654,344 residents rely on Medi-Cal. And that's just a fraction of the many across the capital region who depend on it for healthcare. That includes many of the workers who keep our restaurants running, care for our children and elders and staff our hospitals and schools. When they lose access to healthcare, it doesn't just hurt them—it hurts the businesses that depend on them. Missed shifts, higher turnover, rising costs: These are not abstract consequences but are the daily realities employers will face if this bill becomes law. It doesn't stop there. By slashing tax credits that help families afford childcare, transportation and school supplies, H.R.-1 makes it harder for parents to stay in the workforce. By capping student loan forgiveness, it narrows the pipeline into critical professions like teaching, nursing and skilled trades—fields already stretched thin. We've seen this story before. When the safety net is pulled away, the burden doesn't disappear. It shifts—to employers, to local governments, to communities already doing more with less. Businesses are left to absorb the costs of instability: more sick days, more training, more churn. And over time, that instability becomes a drag on growth, innovation and competitiveness. But here's the good news: We don't have to accept this. Sacramento's business community has a proud tradition of stepping up—not just for profit, but for people. We've seen what's possible when business leaders use their voices to advocate for opportunity and shared prosperity so our entire community thrives. Now is one of those moments. We urge every employer, every entrepreneur, every chamber of commerce and boardroom in this region to take a stand. Call your representatives. Make it clear that gutting the programs that support our workforce is not just bad policy—it's bad business. Because the truth is, when we invest in people, we all rise. When we protect the health and dignity of workers, we build stronger companies. When we ensure that every child has a shot at success, we secure the future of our economy. This is about who we are—and who we want to be. Let's choose a Sacramento where businesses thrive because families are strong. Let's choose a future where prosperity lifts everyone—not just a few. Let's reject H.R.-1 and stand up for the values that make our community resilient, compassionate, and bold.
CNBC
8 hours ago
- CNBC
On the hunt for cheap stocks due for a second half bounce with Morningstar
Health care stocks could be the place to hide out for investors bracing for what many expect will be a volatile second half of the year. The industry is just starting to outperform, as traders rotate into a sector that is starting to look cheap after lagging this year. S & P 500 health care stocks are selling at 17 times forward earnings, far below their historical valuation. The entire S & P 500 sells for 23 times forward P/E. Exclude Eli Lilly , a high-flier thanks to its diabetes- and obesity treatments, and health care looks even more attractively valued. Lilly trades at 36 times forward earnings. "Healthcare looks very undervalued to us here, especially because healthcare is skewed to the upside, because [of] Eli Lilly," said Dave Sekera, chief U.S. market strategist for Morningstar. "Eli Lilly is overvalued. We think the market is over extrapolating the amount of profitability and growth in the GLP-1 drugs, which Eli Lilly, of course, is, you know, the the poster child for today." "If you were to take that out, the healthcare sector, as a sector, looks even more undervalued today," Sekera said, presenting an opportunity for investors. .GSPHC YTD mountain S & P 500 health care sector, year to date On Tuesday, the Dow Jones Industrial Average , which contains health care giants UnitedHealth Group , Johnson & Johnson , Amgen and Merck rallied, while the S & P 500 and Nasdaq Composite, which are weighted toward tech stocks that led the recent advance, retreated. Health care's relatively cheap valuations and above-average dividend yields give investors a "margin of safety" heading into the second half of the year, when the S & P 500 starts to look fairly valued at the same time as risks from tariffs and federal deficits continue, Sekera said. The strategist said he likes other beaten down parts of the market too, citing a preference for value stocks over growth issues and small caps over large caps. "Right now, I would actually prefer to see a greater margin of safety in the marketplace as a cushion for absorbing that amount of risk ," Sekera said. "With the market being at fair value, I think positioning is ever more important than usual."
